CapWealth Advisors LLC Has $12.68 Million Holdings in Stryker Corporation $SYK

Key Points

• CapWealth Advisors boosted its Stryker stake by 18.2% in Q4 to 36,069 shares, valued at about $12.68 million.
• Stryker missed Q1 estimates (EPS $2.60 vs. $2.98; revenue $6.02B vs. $6.34B) after a cyber incident disrupted production and pressured margins, but management maintained FY‑2026 guidance of $14.90–$15.10 adjusted EPS and 8%–9.5% organic sales growth while reporting improved operating cash flow and net income year‑over‑year.
• Director Ronda E. Stryker sold 250,000 shares for roughly $90.7M; Wall Street ratings average a "Moderate Buy" (16 Buys, 6 Holds) with an average price target of $401.43 while the stock trades near $295 (52‑week high $404.87).

CapWealth Advisors LLC boosted its stake in Stryker Corporation (NYSE:SYK - Free Report) by 18.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 36,069 shares of the medical technology company's stock after purchasing an additional 5,558 shares during the quarter. CapWealth Advisors LLC's holdings in Stryker were worth $12,677,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of SYK. United Financial Planning Group LLC acquired a new position in Stryker during the third quarter worth about $27,000. Strive Asset Management LLC acquired a new position in Stryker during the third quarter worth about $30,000. ANTIPODES PARTNERS Ltd acquired a new position in Stryker during the third quarter worth about $34,000. Copia Wealth Management raised its stake in Stryker by 181.6% during the third quarter. Copia Wealth Management now owns 107 shares of the medical technology company's stock worth $40,000 after acquiring an additional 69 shares in the last quarter. Finally, WPG Advisers LLC raised its stake in Stryker by 156.8% during the third quarter. WPG Advisers LLC now owns 113 shares of the medical technology company's stock worth $42,000 after acquiring an additional 69 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on SYK shares. William Blair reissued an "outperform" rating on shares of Stryker in a research note on Thursday, March 5th. Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a research note on Friday. Sanford C. Bernstein set a $410.00 target price on Stryker in a research note on Friday. Piper Sandler reissued an "overweight" rating on shares of Stryker in a research note on Tuesday, January 27th. Finally, Leerink Partners started coverage on Stryker in a research note on Monday, April 13th. They set an "outperform" rating and a $410.00 target price for the company. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $401.43.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker maintained its FY‑2026 outlook — $14.90–$15.10 adjusted EPS and 8%–9.5% organic sales growth — signaling management’s confidence in recovery from the cyber incident. Article Title
• Positive Sentiment: Operational cash flow and net income showed notable improvement year-over-year (operating cash flow jumped and net income rose), which supports longer‑term cash generation and capital investment. Article Title
• Neutral Sentiment: Stryker will present at the Bank of America Global Healthcare Conference on May 13 — an opportunity for management to address the cyber recovery and investor questions, but not an immediate catalyst for results. Article Title
• Negative Sentiment: Q1 results missed consensus: adjusted EPS of $2.60 vs. ~ $2.98 expected and revenue of $6.02B vs. ~$6.34B. Management cited a cyber incident that disrupted production, pressured margins and slowed growth — the primary driver of today’s selling pressure. Article Title
• Negative Sentiment: Several Wall Street firms cut Stryker price targets this morning (JPMorgan to $400, Wells Fargo to $418, Needham/BTIG lowered targets) — ratings largely remain buy/overweight but lower targets reduce near‑term upside expectations and add selling pressure. Article Title

Stryker Stock Performance

NYSE:SYK opened at $295.43 on Friday. The company has a market capitalization of $113.15 billion, a PE ratio of 35.17, a P/E/G ratio of 1.84 and a beta of 0.92. The company has a 50 day simple moving average of $345.67 and a two-hundred day simple moving average of $356.95. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. Stryker Corporation has a fifty-two week low of $294.55 and a fifty-two week high of $404.87.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts' consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.74%. The business's revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the prior year, the company posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts anticipate that Stryker Corporation will post 14.91 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend was Tuesday, March 31st. Stryker's dividend payout ratio is currently 41.90%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the completion of the sale, the director owned 2,457,331 shares of the company's stock, valued at approximately $891,814,566.52. This represents a 9.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.60% of the company's stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.